Observational Study to Monitor Safety and Effectiveness of Obinutuzumab in Follicular Lymphoma or Previously Untreated Chronic Lymphocytic Leukemia
This study aims to collect clinical data, mainly focused on safety, in the local target population as per the requirement of Korea Ministry of Food and Drug Safety for market authorization. The study population comprises patients with approved local indications chronic lymphocytic leukemia (CLL) and/or follicular lymphoma (FL) in routine clinical practice after launch.
Chronic Lymphocytic Leukemia|Follicular Lymphoma
BIOLOGICAL: obinutuzumab
Percentage of Participants with Serious Adverse Event (AE)/Adverse Drug Reaction (ADR), from baseline until the end of the participant's observation period (up to approximately 8 years)|Percentage of Participants with Unexpected AE/ADR, from baseline until end of the participant's observation period (up to approximately 8 years)|Percentage of Participants with Expected ADR, from baseline until end of the participant's observation period (up to approximately 8 years)|Percentage of Participants with Non-serious ADR, from baseline until end of the participant's observation period (up to approximately 8 years)|Percentage of Participants with AEs of Special Interest (AESIs), from baseline until end of the participant's observation period (up to approximately 8 years)
Overall Response Rate, According to International Workshop on Chronic Lymphocytic Leukemia (IWCLL) 2008 for CLL or Cheson 2014 criteria for FL, from baseline until end of the participant's observation period (up to approximately 8 years)|Stable Disease Rate, According to IWCLL 2008 for CLL or Cheson 2014 criteria for FL, from baseline until end of the participant's observation period (up to approximately 8 years)|Progressive Disease Rate, According to IWCLL 2008 for CLL or Cheson 2014 criteria for FL, from baseline until end of the participant's observation period (up to approximately 8 years)
This study aims to collect clinical data, mainly focused on safety, in the local target population as per the requirement of Korea Ministry of Food and Drug Safety for market authorization. The study population comprises patients with approved local indications chronic lymphocytic leukemia (CLL) and/or follicular lymphoma (FL) in routine clinical practice after launch.